The Cardiovascular Risk in Cushing’s Syndrome

1. R. Pivonello, M.C. de Martino, M. de Leo,L. Tauchmanovà, A. Faggiano, G. Lombardi, Cushing’s syndrome: Aftermath of the cure, Arq Bras Endocrinol Metabol, 51 (2007), pp. 1381-1391.10.1590/S0004-27302007000800025Search in Google Scholar

2. E. Valassi, I. Crespo, A. Santos, S.M. Webb, Clinical consequences of Cushing’s syndrome, Pituitary, 15 (2012), pp. 319-329.2252761710.1007/s11102-012-0394-822527617Search in Google Scholar

3. R.A. Feelders, S.J. Pulgar, A. Kempel, A.M. Pereira, The burden of Cushing’s disease: clinical and health-related quality of life aspects, Eur J Endocrinol, 167 (2012), pp. 311-326.10.1530/EJE-11-1095Search in Google Scholar

4. E. Valassi, A. Santos, M. Yaneva, M. Toth, C.J. Strasburger, P. Chanson, The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics, Eur J Endocrinol, 165 (2011), pp. 383-392.10.1530/EJE-11-0272Search in Google Scholar

5. A. Colao, R. Pivonello, S. Spiezia, A. Faggiano, D. Ferone, M. Filippella, Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure, J Clin Endocrinol Metab, 84 (1999), pp. 2664-2672.10.1210/jcem.84.8.5896Search in Google Scholar

6. Y. Liu, Y. Nakagawa, Y. Wang, R. Li, X. Li, T. Ohzeki, Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice, Diabetes, 52 (2003), pp. 1409-1416.10.2337/diabetes.52.6.14091276595112765951Open DOISearch in Google Scholar

7. M.J. Barahona, N. Sucunza, E. Resmini, J.M. Fernández-Real, W. Ricart, J.M. Moreno-Navarrete, Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing’s syndrome, J Clin Endocrinol Metab, 94 (2009), pp. 3365-3371.1950910110.1210/jc.2009-076619509101Search in Google Scholar

8. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect Cushing’s disease of the omentum? Lancet. 1997;349:1210–3.10.1016/S0140-6736(96)11222-8Search in Google Scholar

9. Andrews RC, Herlihy O, Livingstone DE. et al. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. J Clin Endocrinol Metab. 2002;87:5587–93.10.1210/jc.2002-02004812466357Search in Google Scholar

10. Reynolds RM, Chapman KE, Seckl JR. et al. Skeletal muscle glucocorticoid receptor density and insulin resistance. JAMA. 2002;287:2505–6.10.1001/jama.287.19.250512020330Search in Google Scholar

11. M. De Leo, R. Pivonello, R.S. Auriemma, A. Cozzolino, P. Vitale, C. Simeoli, Cardiovascular disease in Cushing’s syndrome: heart v ersus vasculature, Neuroendocrinology, 92 (2010), pp. 50-54.10.1159/00031856620829618Open DOISearch in Google Scholar

12. Giraldi FP, Moro M, Cavagnini F. Study Group on the Hypothalamo-Pituitary-Adrenal Axis of the Italian Society of Endocrinology. Gender-related differences in the presentation and course of Cushing’s disease. J Clin Endocr Metab 2003;88:1554–1558.10.1210/jc.2002-02151812679438Open DOISearch in Google Scholar

13. Mancini T, Kola B, Concettoni C, Boscaro M, Mantero F, Arnaldi G. Hypertension in patients with Cushing’s syndrome: Evidence for gender difference in 11β hydroxysteroid dehydrogenase type 2 activity. The Endocrine Society 85nd Annual Meeting, Philadelphia, P2-606, 2003;454.Search in Google Scholar

14. Magiakou MA, Mastrokaros G, Olfield EA, Gomez MT, Doppman JL, Cutler GBJ, Nieman LK. Chrousos GP Cushing’s syndrome in children and adolescents: Presentation, diagnosis and therapy. New England J Med 1994;331:629–636.10.1056/NEJM1994090833110028052272Search in Google Scholar

15. Biglieri EG, Kater CE, Mantero F. Adrenocortical forms of human hypertension. In: Laragh, Brenner (Eds), Hypertension, 2nd edn. Raven Press, 1995:2145.Search in Google Scholar

16. Arnaldi G, Mancini T, Tirabassi G. et al. Advances in the epidemiology, pathogenesis, and management of Cushing’s syndrome complications. J Endocrin Invest. 2012;35:434–38.10.1007/BF0334543122652826Search in Google Scholar

17. Magiakou MA, Smyrnaki P, Chrousos GP: Hypertension in Cushing’s syndrome. Best Pract Res Clin Endocrinol Metab 2006;20:467–482.10.1016/j.beem.2006.07.00616980206Search in Google Scholar

18. Pecori Giraldi F, Toja PM, De Martin M, Maronati A, Scacchi M, Omboni S, Cavagnini F, Parati G: Circadian blood pressure profile in patients with active Cushing’s disease and after long-term cure. Horm Metab Res 2007;39:908–914.10.1055/s-2007-992813Search in Google Scholar

19. Muiesan ML, Lupia M, Salvetti M, Grigoletto C, Sonino N, Boscaro M, Rosei EA, Mantero F, Fallo F: Left ventricular structural and functional characteristics in Cushing’s syndrome. J Am Coll Cardiol 2003;41:2275–2279.10.1016/S0735-1097(03)00493-5Open DOISearch in Google Scholar

20. Pereira AM, Delgado V, Romijn JA, Smit JW, Bax JJ, Feelders RA: Cardiac dysfunction is reserved upon successful treatment of Cushing’s syndrome. Eur J Endocrinol 2010;162:331–340.10.1530/EJE-09-062119933822Search in Google Scholar

21. B. Van Zanne,E. Nur,A. Squizzato,O.M. Dekkers,M.T. Twickler,E. Fliers, Hypercoagulable state in Cushing’s syndrome: a systematic review, J Clin Endocrinol Metab, 94 (2009), pp. 2743-2750.10.1210/jc.2009-029019454584Open DOISearch in Google Scholar

22. L. Manetti,F. Bogazzi,C. Giovannetti,V. Raffaelli,M. Genovesi,G. Pellegrini, Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing’s syndrome: results from a prospective study before and after surgery, Eur J Endocrinol, 163 (2010), pp. 783-791.10.1530/EJE-10-0583Search in Google Scholar

23. Ermetici F, Malavazos AE, Corbetta S, Eller-Vainicher C, Cannavò S, Corsi MM, Ambrosi B: Soluble adhesion molecule levels in patients with Cushing’s syndrome before and after cure. J Endocrinol Invest 2008;31:389–392.10.1007/BF0334638118560255Open DOISearch in Google Scholar

24. Kristo C, Ueland T, Godang K, Aukrust P, Bollerslev J: Biochemical markers for cardiovascular risk following treatment in endogenous Cushing’s syndrome. J Endocrinol Invest 2008;31:400–405.10.1007/BF0334638318560257Open DOISearch in Google Scholar

25. Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT, Patrassi GM, Girolami A: Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing’s syndrome. J Clin Endocrinol Metab 2002;87:3662–3666.10.1210/jcem.87.8.8703Search in Google Scholar

26. Terzolo M, Allasino B, Bosio S, Brusa E, Daffara F, Ventura M, Aroasio E, Sacchetto G, Reimondo G, Angeli A, Camaschella C: Hyperhomocysteinemia in patients with Cushing’s syndrome. J Clin Endocrinol Metab 2004;89:3745–3751.10.1210/jc.2004-0079Search in Google Scholar

27. Faggiano A, Melis D, Alfieri R, De Martino M, Filippella M, Milone F, Lombardi G, Colao A, Pivonello R: Sulfur amino acids in Cushing’s disease: insight homocysteine and taurine levels in patients with active and cured disease. J Clin Endocrinol Metab 2005;90:6616–6622.10.1210/jc.2005-065616174722Open DOISearch in Google Scholar

28. M.J. Barahona,E. Resmini,D. Viladés,G. Pons-Lladó,R. Leta,T. Puig, Coronary artery disease detected by multislice computed tomography in patients after long-term cure of Cushing’s syndrome, J Clin Endocrinol Metab, 98 (2013), pp. 1093-1099.10.1210/jc.2012-354723393183Open DOISearch in Google Scholar

29. Baykan M, Erem C, Gedikli O. et al. Impairment of flow-mediated vasodilatation of brachial artery in patients with Cushing’s Syndrome. Endocrine. 2007;31:300–4.10.1007/s12020-007-0033-817906379Open DOISearch in Google Scholar

30. Prázný M, Jezková J, Horová E. et al. Impaired microvascular reactivity and endothelial function in patients with Cushing’s syndrome: influence of arterial hypertension. Physiol Res. 2008;57:13–22.10.33549/physiolres.93112617223725Search in Google Scholar

31. Neary NM, Booker OJ, Abel BS. et al. Hypercortisolism is associated with increased coronary arterial atherosclerosis: analysis of noninvasive coronary angiography using multidetector computerized tomography. J Clin Endocrinol Metab. 2013;98:2045–52.10.1210/jc.2012-3754364459823559084Search in Google Scholar

32. Schneider HJ, Dimopoulou C, Stalla GK, Reincke M & Schopohl J. Discriminatory value of signs and symptoms in Cushing’s syndrome revisited: what has changed in 30 years? Clinical Endocrinology 2013 78 153–154.10.1111/j.1365-2265.2012.04488.x22775352Open DOISearch in Google Scholar

33. Shen J, Sun M, Zhou B & Yan J. Nonconformity in the clinical practice guidelines for subclinical Cushing’s syndrome: which guidelines are trustworthy? European Journal Endocrinology 2014 171 421–431.10.1530/EJE-14-034524986532Search in Google Scholar

34. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Alì A, Giovagnetti M, Opocher G & Angeli A. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. Journal of Clinical Endocrinology and Metabolism 2000 85 637–644.10.1210/jc.85.2.637Search in Google Scholar

35. Terzolo M, Pia A, Alì A, Osella G, Reimondo G, Bovio S, Daffara F, Procopio M, Paccotti P, Borretta G et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? Journal of Clinical Endocrinology and Metabolism 2002 87 998–1003.10.1210/jcem.87.3.827711889151Search in Google Scholar

36. Chiodini I. Clinical review: diagnosis and treatment of subclinical hypercortisolism. Journal of Clinical Endocrinology and Metabolism 2011 96 1223–1236.10.1210/jc.2010-272221367932Open DOISearch in Google Scholar

37. Shen J, Sun M, Zhou B & Yan J. Nonconformity in the clinical practice guidelines for subclinical Cushing’s syndrome: which guidelines are trustworthy? European Journal Endocrinology 2014 171 421–43110.1530/EJE-14-0345Search in Google Scholar